Cellectar Biosciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $75.30 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2018-03-31 was $1.89.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2016-03-31 was $36.44.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $75.30, a 3821.88% increase from fiscal 2023.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $1.92.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2016 was $7.00, a 91.48% decline from fiscal 2015.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2015 was $82.20, a 43.62% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 98 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | $75.30 10-K · filed 2026-03-04 | $2.51 10-K · filed 2025-03-13 | ||||
| 2023-12-31 | $1.92 10-K · filed 2025-03-13 | |||||
| 2018-06-30 | $19.30 10-Q · filed 2018-08-10 | |||||
| 2018-03-31 | $1.89 10-Q · filed 2018-05-11 | |||||
| 2017-09-30 | $1.48 10-Q · filed 2017-11-09 | |||||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-14 | |||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-11 | |||||
| 2016-12-31 | $7.00 10-K · filed 2017-03-15 | |||||
| 2016-09-30 | $3.22 10-Q · filed 2016-11-10 | |||||
| 2016-06-30 | $140.86 10-Q · filed 2016-08-11 | |||||
| 2016-03-31 | $36.44 10-Q · filed 2016-05-12 | |||||
| 2015-12-31 | $82.20 10-K · filed 2017-03-15 | |||||
| 2015-09-30 | $8.22 10-Q · filed 2015-11-12 | |||||
| 2015-06-30 | $9.29 10-Q · filed 2015-08-12 | |||||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-20 | |||||
| 2014-12-31 | $145.80 10-K/A · filed 2016-10-20 | $14.58 10-K · filed 2015-03-24 | ||||
| 2014-09-30 | $15.00 10-Q · filed 2015-05-20 | |||||
| 2014-06-30 | $15.00 10-Q · filed 2014-08-04 | |||||
| 2014-03-31 | $0.75 10-Q · filed 2014-05-14 | |||||
| 2013-12-31 | $15.60 10-K · filed 2015-05-20 | $0.78 10-K · filed 2014-03-19 | ||||
| 2013-09-30 | $0.81 10-Q · filed 2013-11-13 | |||||
| 2013-03-31 | $0.75 10-Q · filed 2013-08-12 | |||||
| 2012-12-31 | $1.38 10-K · filed 2014-03-19 | |||||
| 2012-09-30 | $1.36 10-Q · filed 2012-11-06 | |||||
| 2011-12-31 | $2.46 10-K · filed 2014-03-19 | $2.44 10-K · filed 2013-03-28 | ||||
| 2010-12-31 | $2.91 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |